Does exogenous glucose-dependent insulinotropic polypeptide (GIP) effect gastric emptying and glycaemic response to small intestinal nutrient in critically ill patients?
The effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) on gastric emptying and glucose metabolism in critically ill patients
Adam Deane
25 participants
Apr 18, 2012
Interventional
Conditions
Summary
The primary objective of this study is to establish if exogenous glucose-dependent insulinotropic polypeptide (GIP) has a glucose lowering effect in critically ill patients and whether it effects gastric emptying
Eligibility
Inclusion Criteria3
- Mechanically ventilated critically ill patients.
- Suitable for, or receiving post-pyloric nutrition.
- Likely to stay ventilated for at least 48 hours.
Exclusion Criteria6
- History of diabetes
- Pregnancy
- Haemoglobin <80g/L
- Contraindication to enteral feeding
- Previous surgery to small intestine
- Any gastrointestinal surgery during admission
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Study Drug: Glucose-dependent insulinotropic polypeptide (GIP) at 4pmol.kg.min Infused intravenously at rate of 1ml/min from 0-360mins Patients will be studied on 2 consecutive days (i.e. 24 hour washout period)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000488808